Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer

Completed

Conditions studied: Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases, Colorectal Cancer

In brief

The primary objective is to determine the sensitivity and specificity of the Exact Colorectal Cancer (CRC) screening test for colorectal cancer, using colonoscopy as the reference method. Lesions will be confirmed as malignant by histopathologic examination. The secondary objective is to compare the performance of the Exact CRC screening test to a commercially available FIT assay, both with respect to cancer and advanced adenoma. Lesions will be confirmed as malignant or precancerous by colonoscopy and histopathologic examination.

Key facts

Study ID

NCT01397747

Run by

Exact Sciences Corporation

People needed

12776

Starts

2011-06-01

Expected to finish

2013-05-01

Last updated by the study team

2015-12-03

Who can join

Age: 50 and older, up to 84. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subject is average risk for development of colorectal cancer (as defined by the inclusion and exclusion criteria below).
• Subject is able and willing to undergo a screening colonoscopy within 90 days of enrollment.
• Subject is 50 to 84 years of age inclusive.
• Subject is able to comprehend, sign, and date the written informed consent document to participate in the study.
• Subject is able and willing to provide stool samples according to written instructions provided to them.

You may not qualify if…

• Subject has any condition which, in the opinion of the investigator should preclude participation in the study.
• Subject has undergone colonoscopy within the previous nine (9) years.
• Subject has undergone any double-contrast barium enema, virtual (CT-based) colonoscopy, or flexible sigmoidoscopy within the previous five (5) years.
• Subject has a history of colorectal cancer or adenoma.
• Subject has a history of aerodigestive tract cancer.
• Subject has had a positive fecal occult blood test or FIT within the previous six (6) months.
• Subject has had a prior colorectal resection for any reason other than sigmoid diverticular disease.
• Subject has had overt rectal bleeding, e.g., hematochezia or melena, within the previous 30 days. (Blood on toilet paper, after wiping, does not constitute rectal bleeding).
• Subject has a diagnosis or personal history of any of the following high-risk conditions for colorectal cancer:
• Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease.
• >= 2 first-degree relatives who have been diagnosed with colon cancer. (Note: first-degree relatives include parents, siblings and offspring).
• One first-degree relative with CRC diagnosed before the age of 60.
• Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP).
• Hereditary non-polyposis colorectal cancer syndrome (also referred to as "HNPCC" of "Lynch Syndrome").
• Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardner's Syndrome, Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Cronkhite-Canada Syndrome, Neurofibromatosis and Familial Hyperplastic Polyposis.
• Subject has a family history of:
• Familial adenomatous polyposis (also referred to as "FAP").
• Hereditary non-polyposis colorectal cancer syndrome (also referred to as "HNPCC" or "Lynch Syndrome").
• Participation in any "interventional" clinical study within the previous 30 days in which an experimental treatment is administered or might be administered through a randomized assignment of the subject to one or more study groups.

Where it is running

• Mayo Clinic Scottsdale — Scottsdale, Arizona, United States
• Desert Sun Clinical Research, LLC — Tucson, Arizona, United States
• HealthCare Partners — Alhambra, California, United States
• HealthCare Partners — Arcadia, California, United States
• Valley Gastro Consultants — Arcadia, California, United States
• Desert Oasis Healthcare — Bermuda Dunes, California, United States
• HealthCare Partners — Burbank, California, United States
• REMEK Research — Chino, California, United States
• Southern California Oncology — Downey, California, United States
• HealthCare Partners Medical Group — El Monte, California, United States
• Southern California Oncology — Fullerton, California, United States
• HealthCare Partners — Glendale, California, United States
• HealthCare Partners — Glendale, California, United States
• Valley Gastro Consultants — Glendora, California, United States
• HealthCare Partners — Huntington Park, California, United States
• Health Care Partners Medical Group — Long Beach, California, United States
• Health Care Partners San Antonio — Long Beach, California, United States
• VA Hospital — Long Beach, California, United States
• Healthcare Partners Medical Group — Los Angeles, California, United States
• HealthCare Partners — Los Angeles, California, United States
• HealthCare Partners — Los Angeles, California, United States
• Southern California Oncology — Lynwood, California, United States
• Facey Medical Foundation — Mission Hills, California, United States
• Healthcare Partners- Mission Plaza — Mission Hills, California, United States
• Achieve Clinical Research — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.